BridgeBio Pharma Files 8-K: Material Agreement Announced

TL;DR

BridgeBio filed an 8-K on 3/5/24, announcing a material definitive agreement. Details TBD.

AI Summary

BridgeBio Pharma, Inc. announced on March 5, 2024, that it entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits as part of this 8-K filing. Specific details regarding the agreement and financial information were not provided in the excerpt.

Why It Matters

This filing indicates a significant development for BridgeBio Pharma, potentially involving new partnerships, acquisitions, or financing that could impact its future operations and stock value.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could represent significant opportunities or risks for the company, but the lack of specific details makes the immediate risk level uncertain.

Key Players & Entities

• BridgeBio Pharma, Inc. (company) — Registrant
• March 5, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share BBIO The Nasdaq Global Se
• $29.00 — on Stock"), at a price to the public of $29.00 per share. The Company granted the Unde
• $250.0 m — e by the Company, will be approximately $250.0 million, excluding any exercise of the Un

Filing Documents

• ny20019103x3_8k.htm (8-K) — 31KB
• ny20019103x3_ex1-1.htm (EX-1.1) — 197KB
• ny20019103x3_ex5-1.htm (EX-5.1) — 9KB
• ny20019103x3_ex99-1.htm (EX-99.1) — 9KB
• ny20019103x3_ex99-2.htm (EX-99.2) — 9KB
• ny20019103x3_ex5-1img01.jpg (GRAPHIC) — 4KB
• 0001140361-24-011766.txt ( ) — 455KB
• bbio-20240305.xsd (EX-101.SCH) — 4KB
• bbio-20240305_lab.xml (EX-101.LAB) — 21KB
• bbio-20240305_pre.xml (EX-101.PRE) — 16KB
• ny20019103x3_8k_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On March 5, 2024, BridgeBio Pharma, Inc. (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters listed on Schedule I thereto (collectively, the "Underwriters"), relating to an underwritten public offering (the "Offering") of 8,620,690 shares of the Company's common stock, $0.001 par value per share (the "Common Stock"), at a price to the public of $29.00 per share. The Company granted the Underwriters a 30-day option to purchase, at the public offering price less underwriting discounts and commissions, up to an additional 1,293,103 shares of Common Stock. The Company estimates net proceeds from the Offering, after deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company, will be approximately $250.0 million, excluding any exercise of the Underwriters' option to purchase additional shares. The Offering is expected to close on or about March 8, 2024, subject to the satisfaction of customary closing conditions. The Company currently expects to use the net proceeds from the Offering to fund the commercial launch of acoramidis, if approved, and the clinical and pre-clinical development of its current and future product candidates, conduct research activities, and for working capital and other general corporate purposes. The Company may also use a portion of the net proceeds to invest in or acquire businesses or technologies that the Company believes are complementary to its own, although it has no current plans, commitments, or agreements with respect to any such material investments or acquisitions as of the date of the Prospectus (as defined in the Underwriting Agreement). These intentions are subject to change. The Company believes that its existing cash and cash equivalents, together with the

01 Other Events

Item 8.01 Other Events. On March 4, 2024, the Company announced the launch of the Offering, and on March 5, 2024, the Company announced the pricing of the Offering. Copies of these press releases are attached to this Current Report on Form 8-K as Exhibits 99.1 and 99.2, respectively, and are each incorporated herein by reference. Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K and certain of the materials filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the Offering. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements, such as those related to the anticipated closing of the Offering, are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Current Report on Form 8-K or the materials furnished or filed herewith, including, without limitation, uncertainties related to market conditions and the completion of the Offering on the anticipated terms or at all. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent

01 Exhibits

Item 9.01 Exhibits. (d) Exhibits 1.1 Underwriting Agreement, dated as of March 5, 2024, by and among the Company, J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several Underwriters listed on Schedule I thereto. 5.1 Opinion of Goodwin Procter LLP. 23.1 Consent of Goodwin Procter LLP (included in Exhibit 5.1). 99.1 Press release for the launch of the Offering issued by the Company on March 4, 2024. 99.2 Press release for the pricing of the Offering issued by the Company on March 5, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document). Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit in accordance with the rules of the Securities and Exchange Commission because such information (i) is not material and (ii) is the type that the Registrant treats as private or confidential.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BRIDGEBIO PHARMA, INC. Date: March 6, 2024 By: /s/ Brian C. Stephenson Brian C. Stephenson Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR